A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05643742 |
|
Recruitment Status :
Recruiting
First Posted : December 9, 2022
Last Update Posted : August 15, 2023
|
Sponsor:
CRISPR Therapeutics AG
Information provided by (Responsible Party):
CRISPR Therapeutics ( CRISPR Therapeutics AG )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 2030 |
| Estimated Study Completion Date : | February 2030 |